SCHEMBL3215162

SCHEMBL3215162

O=C(O)c1ccc(Cl)c(-c2ccc(-c3cncc(CO)c3)cc2)c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MKNK1 Q9BUB5 3/20 0.46
MKNK2 Q9HBH9 3/20 0.46
MAP4K4 O95819 4/20 0.43
DYRK1A Q13627 1/20 0.43
TSHR P16473 1/20 0.41
CYP11B1 P15538 2/20 0.41
CYP11B2 P19099 2/20 0.41
XDH P47989 1/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
SCN2A Q99250 1/20 0.40
SCN10A Q9Y5Y9 1/20 0.40
PRKAB2 O43741 1/20 0.40
PRKAG1 P54619 1/20 0.40
PRKAA2 P54646 1/20 0.40
PRKAA1 Q13131 1/20 0.40
PRKAG3 Q9UGI9 1/20 0.40
PRKAG2 Q9UGJ0 1/20 0.40
PRKAB1 Q9Y478 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3205510 0.87 MKNK1 (0.41) MKNK1MKNK2MAP4K4DYRK1ATSHR
SCHEMBL3217027 0.84 PRKAB2 (0.51) MAP4K4TSHRMEN1KMT2APRKAB2
SCHEMBL3218450 0.83 PRKAB2 (0.52) TSHRMEN1KMT2AL3MBTL1PRKAB2
SCHEMBL3221130 0.82 AR (0.54) MKNK1MKNK2MAP4K4TSHRADH5
SCHEMBL3208925 0.81 BCL2 (0.55) TSHRL3MBTL1RXRARXRB
SCHEMBL3205647 0.79 TSHR (0.50) MAP4K4TSHRMEN1KMT2AL3MBTL1
SCHEMBL3214594 0.78 MKNK1 (0.68) MKNK1MKNK2MAP4K4
SCHEMBL3207475 0.78 SMN1; SMN2 (0.50) TSHRMEN1KMT2ARXRARXRB
SCHEMBL6254017 0.78 TSHR (0.61) MAP4K4TSHRMEN1KMT2AADH5
SCHEMBL3205630 0.77 TSHR (0.55) MAP4K4TSHRMEN1KMT2APRKAB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7683097-B2 Topoisomerase inhibitors Propharmacon Inc. (US) 2010-03-23 US disclosed
US-20070004701-A1 Topoisomerase inhibitors PROPHARMACON, INC. (US) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070004701-A1 Topoisomerase inhibitors TOP1, TOP2A, TOP2B MKNK1 690/4885MKNK2 919/4885MAP4K4 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.